Transplants Don't Boost Overall Survival in High-Risk DLBCL
ATLANTA (IMNG) - In young patients with high-risk diffuse large B-cell lymphoma, autologous stem cell transplantation can push the rate of progression-free survival beyond that achievable with rituximab... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 29, 2013 Category: Cancer & Oncology Source Type: news
Minimally Invasive Breast Biopsy Lags in Texas
PALM BEACH, FLA. (IMNG) - More than a fifth of women in Texas with image-detected breast abnormalities failed to undergo minimally invasive breast biopsy as recently as 2008, according to a review of statewide... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 29, 2013 Category: Cancer & Oncology Source Type: news
US Approves Imatinib for Children With Ph+ Acute Lymphoblastic Leukemia
Imatinib has been approved to treat children newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia, the U.S. Food and Drug Administration announced Jan. 25.Imatinib, a tyrosine... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 29, 2013 Category: Cancer & Oncology Source Type: news
Lenalidomide Branches Out to Lymphoma Therapy
ATLANTA (IMNG) - Lenalidomide, already an important agent in the treatment of multiple myeloma, is also flexing its muscles against non-Hodgkin's lymphomas, reported researchers in two clinical trials... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 29, 2013 Category: Cancer & Oncology Source Type: news
FDA Approves Bevacizumab for Second-Line Combinations
Bevacizumab is now approved by the Food and Drug Administration for use in combination with fluoropyrimidine-irinotecan-based or fluoropyrimidine-oxaliplatin-based chemotherapy for metastatic colorectal... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 29, 2013 Category: Cancer & Oncology Source Type: news
HER2 Status Best Predicts Benefit of Anti-HER2 Therapy
SAN ANTONIO (IMNG) - A variety of biomarkers failed to improve on the results of tumor HER2 status for predicting the benefits of therapy targeting HER2 signaling, based on an analysis of data from the... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 25, 2013 Category: Cancer & Oncology Source Type: news
Resecting Residual Gastrointestinal Stromal Tumors Improved Survival
SAN FRANCISCO (IMNG) - Surgically removing residual gastrointestinal stromal tumors in patients who respond to imatinib therapy significantly increased time to tumor progression to 88 months, compared... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 25, 2013 Category: Cancer & Oncology Source Type: news
Experimental CARS Therapy Breaks Through Relapsed CLL
ATLANTA (IMNG) - Responses to chimeric antigen receptor-modified T-cell therapy have been sustained beyond 2 years in a small cohort of patients with advanced chronic lymphocytic leukemia and no other... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 24, 2013 Category: Cancer & Oncology Source Type: news
Metabolic Syndrome Skews Oncotype DX Reliability
SAN ANTONIO (IMNG) - Metabolic syndrome is a potent independent risk factor for breast cancer recurrence in patients who are otherwise at low risk, based on a widely used 21-gene recurrence score assay.... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 24, 2013 Category: Cancer & Oncology Source Type: news
Neoadjuvant Chemo Renders SLN Biopsy Less Reliable
SAN ANTONIO (IMNG)-The results of a sentinel node biopsy performed after neoadjuvant chemotherapy for breast cancer are often unreliable, new data suggest.Researchers with the German SENTINA trial prospectively... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 24, 2013 Category: Cancer & Oncology Source Type: news
Ki67 in Pretreatment Breast Biopsy Predicts Prognosis
SAN ANTONIO (IMNG) - Immunohistochemical expression of the proliferation marker Ki67 in a pretreatment biopsy of breast cancer is valid as both a positive predictive marker and a negative prognostic marker... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 24, 2013 Category: Cancer & Oncology Source Type: news
Second-Line Docetaxel Benefits Seen For Esophagogastric Cancers
SAN FRANCISCO (IMNG) - Results of a phase III trial support a common clinical practice - giving docetaxel as second-line chemotherapy to patients with advanced adenocarcinomas of the stomach or esophagus... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 24, 2013 Category: Cancer & Oncology Source Type: news
Smoking Ups Mortality Threefold
Both men and women who smoke are three times as likely to die as those who don't.Two large population-based studies have come to the same conclusion: Smokers are almost certainly going to die years and... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 24, 2013 Category: Cancer & Oncology Source Type: news
Statins Cut Risk of Hepatocellular Carcinoma
Statin therapy taken to prevent cardiovascular events also appears to protect against hepatocellular carcinoma, reducing the overall risk for the cancer by 37%, according to the results of a systematic... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 23, 2013 Category: Cancer & Oncology Source Type: news
New Score Helps Predict Late Distant Metastases in ER-Positive Breast Cancer
SAN ANTONIO (IMNG) - A new multigene score called EndoPredict improves on clinical measures for predicting whether estrogen receptor-positive breast cancer will metastasize, especially in the long term.... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 23, 2013 Category: Cancer & Oncology Source Type: news
